Happy New Year, and a Heartfelt Farewell!

Biolysis Weekly Is Coming to a Close

Dear Biolysis Weekly Subscribers,

I hope this message finds you well. It is with mixed emotions that I write to you today to share some important and overdue news regarding this newsletter.

In 2021, while in graduate school, I began this newsletter to share research, countless stories, insights, and updates with you, fostering a community built on mutual interests and shared passions towards publicly traded biotech companies. Your support and engagement have been the driving force behind the initial success of this newsletter, and for that, I am sincerely grateful.

However, life often takes unexpected turns, and I found myself at a crossroads with a new and exciting opportunity. A little over a year ago, I accepted a federal position that came with a set of responsibilities that, unfortunately, conflicted with the continued operation of the newsletter. The conflict of interest is the reason why Biolysis Weekly has not had any publications in a while. The new role involves working for the U.S. government in a regulatory capacity, and in order to adhere to the ethical standards and guidelines associated with the agency’s position, I must make the difficult decision to sunset the newsletter.

This decision has not been made lightly, and it is with a heavy heart that I bid farewell to this community. I want to express my deepest gratitude for the readers and subscribers. Your shared enthusiasm and dedication have made this journey truly remarkable.

While this chapter may be coming to a close, I am optimistic about the opportunities that lie ahead for similar newsletters, or anyone who may want to continue carrying on the torch of Biolysis Weekly, feel free to reach out to me at Spundanvdave@gmail.com.

Thank you again for being a part of this newsletter, as short lived as it was.

Warm regards,

Spundan Dave, MPH, MBA, CPH